Ic‐p‐190: An Amyloid Ligand‐free Optical Retinal Imaging Method to Predict Cerebral Amyloid Pet Status

Soucy, Jean‐Paul; Chevrefils, Claudia; Sylvestre, Jean‐Philippe; Arbour, Jean Daniel; Rhéaume, Marc‐André; Beaulieu, Sylvain; Chayer, Céline; Robillard, Alain; Rosa‐Neto, Pedro; Mathotaarachchi, Sulantha; Nasreddine, Ziad; Gauthier, Serge; Lesage, Frédéric

doi:10.1016/j.jalz.2018.06.2257

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that based on the method, type of textures, and the parameters used, the classification performance of texture features alone could be further optimized. For example, the proprietary method developed by Optina Diagnostics [55] achieved higher accuracy than the texture‐based classification results shown in the second row of Table 2.…”

Section: Discussionmentioning

confidence: 99%

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images

Sharafi

Sylvestre

Chevrefils

et al. 2019

A&D Transl Res & Clin Interv

Self Cite

View full text Add to dashboard Cite

IntroductionThis study investigates the relationship between retinal image features and β-amyloid (Aβ) burden in the brain with the aim of developing a noninvasive method to predict the deposition of Aβ in the brain of patients with Alzheimer's disease.MethodsRetinal images from 20 cognitively impaired and 26 cognitively unimpaired cases were acquired (3 images per subject) using a hyperspectral retinal camera. The cerebral amyloid status was determined from binary reads by a panel of 3 expert raters on 18F-florbetaben positron-emission tomography (PET) studies. Image features from the hyperspectral retinal images were calculated, including vessels tortuosity and diameter and spatial-spectral texture measures in different retinal anatomical regions.ResultsRetinal venules of amyloid-positive subjects (Aβ+) showed a higher mean tortuosity compared with the amyloid-negative (Aβ−) subjects. Arteriolar diameter of Aβ+ subjects was found to be higher than the Aβ− subjects in a zone adjacent to the optical nerve head. Furthermore, a significant difference between texture measures built over retinal arterioles and their adjacent regions were observed in Aβ+ subjects when compared with the Aβ−. A classifier was trained to automatically discriminate subjects combining the extracted features. The classifier could discern Aβ+ subjects from Aβ− subjects with an accuracy of 85%.DiscussionSignificant differences in texture measures were observed in the spectral range 450 to 550 nm which is known as the spectral region known to be affected by scattering from amyloid aggregates in the retina. This study suggests that the inclusion of metrics related to the retinal vasculature and tissue-related textures extracted from vessels and surrounding regions could improve the discrimination performance of the cerebral amyloid status.

show abstract

Section: Discussionmentioning

confidence: 99%

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images

Sharafi

Sylvestre

Chevrefils

et al. 2019

A&D Transl Res & Clin Interv

Self Cite

View full text Add to dashboard Cite

show abstract

AIM in Neurodegenerative Diseases: Parkinson and Alzheimer

Davids

Ashrafian

2021

Artificial Intelligence in Medicine

View full text Add to dashboard Cite

Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic

Bader,

Groot,

Tan

et al. 2024

Alz Res Therapy

View full text Add to dashboard Cite

Background Alzheimer’s disease (AD) is a common, complex and multifactorial disease that may require screening across multiple routes of referral to enable early detection and subsequent future implementation of tailored interventions. Blood- and eye-based biomarkers show promise as low-cost, scalable and patient-friendly tools for early AD detection given their ability to provide information on AD pathophysiological changes and manifestations in the retina, respectively. Eye clinics provide an intriguing real-world proof-of-concept setting to evaluate the performance of these potential AD screening tools given the intricate connections between the eye and brain, presumed enrichment for AD pathology in the aging population with eye disorders, and the potential for an accelerated diagnostic pathway for under-recognized patient groups. Methods The BeyeOMARKER study is a prospective, observational, longitudinal cohort study aiming to include individuals visiting an eye-clinic. Inclusion criteria entail being ≥ 50 years old and having no prior dementia diagnosis. Excluded eye-conditions include traumatic insults, superficial inflammation, and conditions in surrounding structures of the eye that are not engaged in vision. The BeyeOMARKER cohort (n = 700) will undergo blood collection to assess plasma p-tau217 levels and a brief cognitive screening at the eye clinic. All participants will subsequently be invited for annual longitudinal follow-up including remotely administered cognitive screening and questionnaires. The BeyeOMARKER + cohort (n = 150), consisting of 100 plasma p-tau217 positive participants and 50 matched negative controls selected from the BeyeOMARKER cohort, will additionally undergo Aβ-PET and tau-PET, MRI, retinal imaging including hyperspectral imaging (primary), widefield imaging, optical coherence tomography (OCT) and OCT-Angiography (secondary), and cognitive and cortical vision assessments. Results We aim to implement the current protocol between April 2024 until March 2027. Primary outcomes include the performance of plasma p-tau217 and hyperspectral retinal imaging to detect AD pathology (using Aβ- and tau-PET visual read as reference standard) and to detect cognitive decline. Initial follow-up is ~ 2 years but may be extended with additional funding. Conclusions We envision that the BeyeOMARKER study will demonstrate the feasibility of early AD detection based on blood- and eye-based biomarkers in alternative screening settings, and will improve our understanding of the eye-brain connection. Trial registration The BeyeOMARKER study (Eudamed CIV ID: CIV-NL-23–09-044086; registration date: 19th of March 2024) is approved by the ethical review board of the Amsterdam UMC.

show abstract

Ic‐p‐190: An Amyloid Ligand‐free Optical Retinal Imaging Method to Predict Cerebral Amyloid Pet Status

Cited by 3 publications

References 0 publications

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images

AIM in Neurodegenerative Diseases: Parkinson and Alzheimer

Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic

Contact Info

Product

Resources

About